glp-1 news today october 9 2025 Poll: 1 in 8 Adults Say They Are Currently Taking a Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford Rising use of GLP-1 medications

Description

, A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis, New England Journal of Medicine 391 (2024): 311319

doi: 10.1111/ddg.14433

Both Wegovy and Ozempic are brand names for the active ingredient semaglutide

Patients with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) should avoid these medications due to the potential risk of thyroid C-cell tumors

In one study, microdosing GLP-1s supported moderate weight loss of up to 10 pounds over 40 weeks in participants. MICRODOSING GLP-1 BENEFITS Do More, Age Less Modulated inflammatory pathways in clinical trials. Studies found a reduced risk of cognitive decline Supported cardiovascular health in clinical trials Improved mitochondrial function and oxidative stress in clinical trials Low doses reduced side effects in clinical trials Supported moderate weight loss of up to 10 pounds over 40 weeks in one study *See studies cited below